20:06:34 EDT Wed 02 Sep 2026
Enter Symbol
or Name
USA
CA



Shattuck Labs Announces Participation in Upcoming September Investor Conferences

2026-09-02 16:05 ET - News Release

AUSTIN, Texas and DURHAM, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that company management will present at and participate in the following upcoming investor conferences:

Conference Details

Wells Fargo 21st Annual Healthcare Conference

Format: Fireside chat and one-on-one meetings
Presenter: Taylor Schreiber, M.D., Ph.D., Chief Executive Officer
Additional Management Participant: Andrew Neill, M.B.A., Chief Financial Officer
Presentation Date: September 8, 2026
Time: 11:00 AM ET
Webcast link:HERE

Cantor Global Healthcare Conference

Format: Fireside chat and one-on-one meetings
Presenter: Taylor Schreiber, M.D., Ph.D., Chief Executive Officer
Additional Management Participant: Andrew Neill, M.B.A., Chief Financial Officer
Presentation Date: September 9, 2026
Time: 3:55 PM ET
Webcast link:HERE

Interested parties can access live audio webcasts of these presentations via the Investor Relations section of the company’s website at www.shattucklabs.com. Replay webcasts will be available for approximately 30 days following the live presentations.

About Shattuck Labs, Inc.
Shattuck Labs, Inc. is a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases. Shattuck’s expertise in protein engineering and the development of novel TNF receptor therapeutics come together in its lead program, SL-325, a potentially first-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the clinically validated DR3/TL1A pathway. The Company has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

Investor & Media Contact:
Andrew R. Neill
Chief Financial Officer
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com


Primary Logo

© 2026 Canjex Publishing Ltd. All rights reserved.